BMS' Sprycel loses out to Novartis' discounted Tasigna in England
06 December 2011
Francesca Bruce
Please Login to read the full article.
06 December 2011
Francesca Bruce
Please Login to read the full article.
RELATED CONTENT
NEWS
- Novartis trumps Bristol-Myers Squibb at NICE for chronic CML
- Patient access scheme prompts NICE U-turn on Novartis' Tasigna, while BMS will appeal against no for Sprycel
- Pfizer's two cancer candidates accepted for EMA review
- NICE U-turn puts Janssen's Zytiga ahead of Sanofi's Jevtana in prostate cancer
ANALYSIS
Other Informa Analysis
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
